



Launch of the ALK Inhibitor “Alecensa[®] Capsule 150mg” -Making Contribution to the Improvement of Convenience of Patients-

TOKYO, December 9, 2015 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it obtained approval from the Ministry of Health, Labour and Welfare on September 2, 2015 for “Alecensa[®] Capsule 150mg,” a high content preparation of the ALK inhibitor “Alecensa[®] Capsule 20mg and 40mg” (generic name: alectinib hydrochloride) sold for the indication of “ALK fusion gene positive unresectable, advanced/recurrent non-small cell lung cancer.” Following its National Health Insurance Drug Price listing on November 28, we launch the “Alecensa[®] Capsule 150mg” today.

Regarding Alecensa, the patients have been obliged to orally take in total of 8 capsules (7 capsules of 40mg preparation and 1 capsule of 20mg preparation) per time, twice daily. Considering great need of a high content preparation to improve convenience of patients, Chugai started developing a 150mg preparation and filed an application in September 2014.

Chugai is convinced that “Alecensa Capsule 150mg” will contribute to the improvement of patients' convenience and satisfaction with treatment, and we continue to put our effort into the improvement of medical care for cancer and the satisfaction of unmet medical needs based on our business philosophy “Innovation all for the patients.”

[Drug information of new Capsule]

Brand name:	Alecensa [®] Capsule 150mg
Generic name:	alectinib hydrochloride
Indications:	ALK fusion gene-positive unresectable, recurrent or advanced non-small cell lung cancer (NSCLC)
Dosage and administration:	The usual adult dosage is 300mg alectinib administered orally twice daily.
Drug price:	6,614.60 yen/capsule
Package:	28 capsules (PTP)